Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Pravachol 80 Mg Long-Term Safety Data Is Phase IV Commitment

Executive Summary

FDA is requesting long-term safety information on the 80 mg and 160 mg strengths of Bristol-Myers Squibb's Pravachol (pravastatin) as a postmarketing commitment associated with the agency's approval of Pravachol 80 mg

You may also be interested in...



Merck Zocor Rhabdomyolysis Risk Is Dose-Related, Revised Warning Says

The risk of myopathy and rhabdomyolysis associated with Merck's Zocor (simvastatin) increases in proportion to the dose, revised labeling says

Merck Zocor Rhabdomyolysis Risk Is Dose-Related, Revised Warning Says

The risk of myopathy and rhabdomyolysis associated with Merck's Zocor (simvastatin) increases in proportion to the dose, revised labeling says

AstraZeneca Crestor NDA Includes Rhabdomyolysis Reports At Highest Dose

AstraZeneca's discussions with FDA about the safety profile of the experimental cholesterol drug Crestor (rosuvastatin) are focusing on the potential for the highest dose to cause rhabdomyolysis, the company indicated during analysts meetings the week of Dec. 3

Related Content

UsernamePublicRestriction

Register

LL111109

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel